Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

Exclusion Criteria

• •Subject has received targeted VEGF/PDGF/TKI therapy. Prior Avastin is allowed
• •Subject has Child-Pugh grade Class C hepatic impairment
• •The subject has proteinuria Common Toxicity Criteria (CTC) grade \> 1 as measured by routine urinalysis or 24 hour urine collection during screening assessment
• •Subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure \> 100 mmHg or systolic blood pressure \> 150 mmHg. Subjects may be re-screened if blood pressure is shown to be controlled with or without intervention
• •The subject has a documented left ventricular Ejection Fraction \< 50%
• •Subject is receiving therapeutic anticoagulation therapy